Comparing AXON and KROS highlights two very different investment profiles in the current market. Axon Enterprise is an established, profitable leader in public safety technology, while Keros Therapeutics is a clinical-stage biotechnology company with no marketed products. A growth-oriented investor focused on recurring revenue and expanding margins may find AXON more familiar, whereas a trader comfortable with binary, catalyst-driven risk may gravitate toward KROS. Understanding their relative performance, market positioning, and risk factors can help clarify which type of opportunity each stock represents.
Axon Enterprise develops and sells public safety technology, including TASER energy devices, body-worn and in-car cameras, drones, digital evidence management software, and AI-enabled tools such as its Draft One report-writing product. The company has increasingly shifted toward a software-as-a-service (SaaS) model, with software and services revenue and annual recurring revenue (ARR) growing rapidly in recent quarters.
Fundamental momentum has remained strong. Recent results have shown revenue growing at roughly 30% or more year over year, with net revenue retention (NRR, a measure of how much existing customers expand their spending) around 125%. Management has also raised its full-year revenue outlook, and future contracted bookings have climbed into the mid-teens of billions of dollars. Despite this, AXON shares have experienced volatility in recent weeks, reflecting broader software-sector multiple compression and investor concerns about valuation rather than deteriorating fundamentals.
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics that target dysfunctional signaling of the TGF-β (transforming growth factor-beta) family of proteins. Its lead wholly owned candidate, rinvatercept, is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), while its most advanced candidate, elritercept, is partnered with Takeda for hematological disorders.
Because Keros has no marketed products, its revenue is driven almost entirely by license and milestone payments, making quarterly results highly uneven. Recent quarters have shown little or no revenue, wider-than-expected losses, and a share price that has declined substantially year to date. The company ended its most recent quarter with cash and cash equivalents around $258 million and expects its runway to fund operations into the first half of 2028, providing time to advance its clinical programs without immediate financing pressure.
For traders looking to navigate comparisons like this systematically, Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots. Tickeron hosts hundreds of AI Trading Bots that monitor thousands of different tickers, but only the ones best suited to current market conditions earn a place in this curated section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they trade, giving users access to a diverse range of automated approaches. Exploring the Trending AI Robots page can help traders identify the strategies currently demonstrating the strongest relative performance across the market.
The most fundamental contrast between AXON and KROS is business maturity. AXON operates a diversified hardware-plus-software ecosystem with recurring subscription revenue, expanding margins, and a large contracted backlog. KROS, by contrast, is pre-commercial and depends on clinical trial outcomes and milestone payments for any near-term revenue.
Growth drivers also differ sharply. AXON's momentum is tied to rising adoption of its AI-enabled software, counter-drone technology, and international and enterprise expansion. KROS's outlook hinges on clinical data readouts—particularly initial Phase 2 data for rinvatercept in DMD, expected in the first half of 2027—and on regulatory progress.
Risk factors diverge as well. AXON faces concentration in government budgets, premium valuation sensitivity, and competitive pressure from established public safety and defense vendors. KROS carries binary clinical risk, reliance on partner milestone economics, and competitive pressure from larger DMD-focused drug developers. On market sentiment, AXON has generally shown steadier institutional positioning despite a recent drawdown, while KROS has displayed more pronounced downside volatility and mixed insider activity.
Based on observable factors such as trend consistency, revenue durability, and catalyst visibility, Tickeron's AI framework would likely favor AXON in the current environment. AXON demonstrates more stable fundamentals, recurring revenue growth, and a diversified product pipeline, which tend to produce a more consistent trend profile. KROS, while offering potentially significant upside tied to clinical catalysts, presents greater uncertainty around revenue timing and near-term momentum. The AI's assessment would therefore lean toward AXON for its relative positioning and stability, while recognizing that KROS remains a higher-risk, catalyst-dependent opportunity.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Indicator for AXON moved into overbought territory on November 20, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 270 of 367 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
KROS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KROS's RSI Oscillator exited the oversold zone, 29 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on KROS as a result. In 75 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for KROS just turned positive on November 17, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
Following a +19.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 224 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
KROS broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KROS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.596). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AXON | KROS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 82 | 100 | |
SMR RATING 1..100 | 81 | 95 | |
PRICE GROWTH RATING 1..100 | 65 | 56 | |
P/E GROWTH RATING 1..100 | 77 | 98 | |
SEASONALITY SCORE 1..100 | 13 | 27 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KROS's Valuation (26) in the null industry is somewhat better than the same rating for AXON (90) in the Biotechnology industry. This means that KROS’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as KROS (100) in the null industry. This means that AXON’s stock grew similarly to KROS’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as KROS (95) in the null industry. This means that AXON’s stock grew similarly to KROS’s over the last 12 months.
KROS's Price Growth Rating (56) in the null industry is in the same range as AXON (65) in the Biotechnology industry. This means that KROS’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (77) in the Biotechnology industry is in the same range as KROS (98) in the null industry. This means that AXON’s stock grew similarly to KROS’s over the last 12 months.
| AXON | KROS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 78% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 79% |
| MACD ODDS (%) | 1 day ago 71% | 1 day ago 72% |
| TrendWeek ODDS (%) | 1 day ago 69% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 77% |
| Advances ODDS (%) | 2 days ago 74% | 3 days ago 76% |
| Declines ODDS (%) | 4 days ago 70% | 1 day ago 75% |
| BollingerBands ODDS (%) | 1 day ago 84% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 79% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while KROS’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 5 bullish TA indicator(s).
AXON (@Aerospace & Defense) experienced а -7.70% price change this week, while KROS (@Biotechnology) price change was +7.57% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -16.06%. For the same industry, the average monthly price growth was -17.09%, and the average quarterly price growth was -35.29%.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
AXON is expected to report earnings on Mar 02, 2027.
KROS is expected to report earnings on Mar 03, 2027.
Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-11.58% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | -5.16% | ||
| TECH - AXON | 61% Loosely correlated | -0.04% | ||
| VCYT - AXON | 58% Loosely correlated | +0.36% | ||
| BEAM - AXON | 57% Loosely correlated | -0.19% | ||
| SEER - AXON | 56% Loosely correlated | -1.81% | ||
| ADPT - AXON | 56% Loosely correlated | -0.43% | ||
More | ||||
A.I.dvisor indicates that over the last year, KROS has been loosely correlated with SANA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then SANA could also see price increases.
| Ticker / NAME | Correlation To KROS | 1D Price Change % | ||
|---|---|---|---|---|
| KROS | 100% | -2.72% | ||
| SANA - KROS | 47% Loosely correlated | -8.62% | ||
| IMNM - KROS | 45% Loosely correlated | -5.54% | ||
| ARVN - KROS | 44% Loosely correlated | -4.15% | ||
| TSHA - KROS | 44% Loosely correlated | -1.33% | ||
| AXON - KROS | 43% Loosely correlated | -5.16% | ||
More | ||||